The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Investigator-assessed PFS improved with atirmociclib plus fulvestrant versus fulvestrant alone or everolimus/exemestane, achieving HR 0.60 and meeting the primary endpoint with clinically meaningful ...
Pfizer said a mid-stage study of its investigational CDK4 inhibitor atirmociclib met its key goal in certain patients with breast cancer. Pfizer on Tuesday said the randomized Phase 2 study met its ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer Inc. is conducting a Phase 1 ...
International variation in diagnostic and treatment practices in patients with HER2+ EBC: The RWE PEARL-HER2 study. Overall survival (OS) in premenopausal ER+/PR+, HER2− breast cancer (BC) treated ...
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results